UNSPSC 51384500: Nonsteroidal anti inflammatory propionates

Nonsteroidal anti inflammatory drugs made from derivatives of propionic acid, which may include acid forms, salts, esters, and amides that contain the carboxyethane structure.

UNSPSC 51384500 Nonsteroidal anti inflammatory propionates is a Class code that in recent state and local procurement appears to span a broader pharmaceutical and health product supply category than the narrow code name suggests. State and local buyers under this code are soliciting naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program capabilities. The issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted recent opportunities, indicating that health departments and state-level procurement offices with multistate reach are active buyers under this code.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's cooperative purchasing framework extending to Oregon and other participating jurisdictions. Seminole County posted IFB 60459723LAS on June 30, 2026 (response due July 26, 2023, with an inconsistent date), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida; vendors must include shipping costs and comply with E-Verify and drug-free workplace certification. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs for self-insured plans and state agencies, signaling preliminary exploration before a formal RFP. MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) sought generic pharmaceuticals and OTC products distributed through three authorized wholesalers with awards effective July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain $5,000,000 commercial general liability insurance and comply with cGMP and Drug Supply Chain Security Act standards.